Skip over navigation
Banner
Industry
Directory Facilities Technology Transfer Economic Develop. IA BioHistory (TM)
Career
Job Search Post a Job Destination IA
News/Events
Industry News Submit News Release Calendar Submit Event CEO Reading
Patient
Clinical Trials Drug Development Resources
Education
K-12 Higher Ed BioEd Reading
About
Advertising Feedback Home
About
 Advertising
 Feedback
 Home
Quick Links
 Directory
 Job Search
 Facilities
 Calendar
 Advertising
 
Community Service Ad:  Every Child Deserves a Chance to Play Baseball
Want to target global biotech trade media?  Use B3C newswire  services.
 
Events
 
UW Master’s in Biomedical Regulatory Affairs: addressing devices, drugs & biologics. Apply now.

Industry News

UW Master’s in Biomedical Regulatory Affairs: addressing devices, drugs & biologics. Apply now.

Submit News Release


Search Articles: 

  • MannKind announces completion of public offering  MannKind announced completion of an underwritten public offering of 35,937,500 units, including 4,687,500 units sold pursuant to the full exercise of an over-allotment option granted underwriters. Gross proceeds from the offering were $86.3 million, before deducting underwriting expenses.
    February 08, 2012  
  • Sangamo BioSciences reports fourth quarter and full year 2011 financial results  Sangamo reported a net loss of $6.4 million for the fourth quarter ended Dec. 31, 2011 versus a net loss of $8.3 million for the same 2010 period. Revenues were $4.7 million for the fourth quarters of both 2011 and 2010. As of Dec. 31, 2011, the Company had cash, and equivalents of $84.5 million.
    February 08, 2012  
  • Hanger Orthopedic Group reports fourth quarter 2011 results  Hanger Orthopedic announced net sales of $248.1 million for the quarter ended December 31, 2011, an increase of $21.6 million, or 9.5%, from $226.5 million for the fourth quarter of 2010. Diluted EPS were $0.52 for the fourth quarter of 2011 versus $0.02 in the same period in 2010.
    February 08, 2012  
  • Neurocrine Biosciences reports fourth quarter and year end 2011 results  Neurocrine reported net income of $37.6 million for the year ended December 31, 2011 versus a net loss of $8.0 million for 2010. Revenues for the year ended December 31, 2011 were $77.4 million, compared with $33.5 million for 2010.
    February 08, 2012  
  • Exelixis announces fourth quarter and full year 2011 financial results  Exelixis reported net income of $46.3 million for the fourth quarter ended December 31, 2011 versus a net loss of ($17.9) million for the comparable period in 2010. Revenues for the fourth quarter ended December 31, 2011 were $93.3 million versus $40.8 million for the comparable 2010 period.
    February 08, 2012  
  • Stereotaxis announces European adoption milestone and Health Canada  Stereotaxis announced that its Vdrive(TM) Robotic Navigation System, which provides physicians the ability to remotely manipulate traditionally non-robotic catheters, is growing in popularity and is expected to surpass 500 clinical procedures in Europe in February.
    February 08, 2012  
  • NIH study links high levels of cadmium, lead in blood to pregnancy delay  Higher blood levels of cadmium in females, and higher blood levels of lead in males, delayed pregnancy in couples trying to become pregnant, according to a study by researchers at the NIH and other academic research institutions.
    February 08, 2012  
  • Array BioPharma announces proposed public offering of common stock  Array BioPharma announced that it is offering to sell shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. Jefferies & Company and Leerink Swann are acting as joint book-running managers of the proposed offering.
    February 08, 2012  
  • Thomas E. Shenk to retire from Merck's board of directors  Merck announced that Thomas E. Shenk, Ph.D., has decided to retire from its board of directors. Dr. Shenk is leaving the board to focus on the new company he is forming to commercialize discoveries made in his Princeton University laboratory in the area of antiviral therapeutics.
    February 08, 2012  
  • CDC study finds levels of trans-fatty acids in blood of U.S. white adults has decreased   Blood levels of trans–fatty acids in white adults in the U.S. population decreased by 58 percent from 2000 to 2009 according to a CDC study published in the Journal of the American Medical Association. This is the first time CDC researchers have been able to measure trans fats in human blood.
    February 08, 2012  

   (next 10 articles)

Submit News Release

 
Email thie page to a friend. Email This Page
to a Friend
Print this page. Print This
Page
© 2012 Info.Resource, Inc. All rights reserved.
Privacy Policy . Terms of Use . Advertising

IowaLifeScience.com is owned and published by Info.Resource, Inc.